Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324041 | 0.86 | HSD17B1 (0.45) | HSD17B1CYP2A6KDM4EHSD17B10RAB9A | |
| SCHEMBL31534041 | 0.85 | HSD17B1 (0.42) | HSD17B1RAB9ANPC1CSNK2A1SMN1; SMN2 | |
| SCHEMBL13137065 | 0.84 | HSD17B1 (0.42) | HSD17B1CYP2A6KDM4EHSD17B10RAB9A | |
| SCHEMBL4677431 | 0.83 | HSD17B1 (0.44) | HSD17B1CYP2A6KDM4EHSD17B10CSNK2A1 | |
| SCHEMBL1549076 | 0.83 | CSNK2A1 (0.53) | HSD17B1KDM4ECSNK2A1SMN1; SMN2KMT2A | |
| SCHEMBL14808369 | 0.82 | HSD17B1 (0.40) | HSD17B1RAB9ANPC1CSNK2A1SMN1; SMN2 | |
| SCHEMBL27005987 | 0.82 | HSD17B1 (0.40) | HSD17B1RAB9ANPC1CSNK2A1SMN1; SMN2 | |
| SCHEMBL4604668 | 0.82 | PARP1 (0.42) | HSD17B1RAB9ANPC1CSNK2A1KMT2A | |
| SCHEMBL21892027 | 0.82 | HSD17B1 (0.40) | HSD17B1KDM4ERAB9ANPC1CSNK2A1 | |
| SCHEMBL9838470 | 0.81 | TAAR1 (0.56) | HSD17B1CYP2A6KDM4EHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20210145832-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20110077394-A1 | LIGHT-DRIVEN ROTARY MOLECULAR MOTORS | NATIONAL SCIENCE FOUNDATION | 2011-03-31 | — | — | US | disclosed |
| WO-1995000114-A1 | TETRALINE® FORMATE ESTER AROMA CHEMICALS | UNION CAMP CORPORATION (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5292719-A | Perfumes, colognes, soaps and cosmetics; musk aroma | UNION CAMP CORPORATION (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | HSD17B1 2383/4885CYP2A6 879/4885KDM4E 1644/4885 |
| US-20210145832-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TNKS, TBKBP1 | HSD17B1 4340/4885CYP2A6 4732/4885KDM4E 802/4885 |
| US-20110077394-A1 | LIGHT-DRIVEN ROTARY MOLECULAR MOTORS | CCNA2, CCNO, SCO2 | HSD17B1 3778/4885CYP2A6 3535/4885KDM4E 3382/4885 |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | ATG7, MLST8, BECN1 | HSD17B1 1210/4885CYP2A6 2379/4885KDM4E 872/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | HSD17B1 898/4885CYP2A6 1885/4885KDM4E 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.